Abstract
Degarelix (Firmagon®), a gonadotropin-releasing hormone (GnRH) receptor antagonist, is indicated as an androgen-deprivation therapy in men with advanced hormone-dependent prostate cancer. It effectively induces and maintains suppression of serum testosterone to castration levels and has an acceptable tolerability profile. Relative to leuprolide, degarelix is associated with more rapid induction of testosterone and prostate-specific antigen (PSA) suppression without the testosterone surges associated with GnRH receptor agonists, and a potentially lower risk of the combined endpoint of PSA progression and death.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
